Vascodagama Online Journal

The Fragile X Syndrome Market Size is anticipated to increase during the study period, 2019–2032

 Breaking News
  • No posts were found

The Fragile X Syndrome Market Size is anticipated to increase during the study period, 2019–2032

November 15
21:12 2022
The Fragile X Syndrome Market Size is anticipated to increase during the study period, 2019–2032

The Fragile X Syndrome market report provides current treatment practices, emerging drugs, Fragile X Syndrome market share of the individual therapies, current and forecasted Fragile X Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Fragile X Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Fragile X Syndrome market.

 

The market is expected to grow by the factors like expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as ZYGEL, BPN14770, OV101, and Trofinetide are anticipated to expand the market with more penetration in the 7MM markets.

 

Key takeaways from the Fragile X Syndrome Market Research Report

  • The increase in Fragile X Syndrome market size is a direct consequence of the increasing prevalent population of Fragile X Syndrome patients in the 7MM.
  • According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Fragile X Syndrome.
  • Fragile X Syndrome Market Companies are working such as Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Ovid Therapeutics, Neuren Pharmaceuticals, and others
  • Fragile X Syndrome Pipeline therapies such as ZYGEL (Cannabidiol/ZYN002), BPN14770, Trofinetide, Sulindac (HLX-0201), and others

 

For further information on the market impact by therapies, download the Fragile X Syndrome sample @ Fragile X Syndrome Market Size

 

Fragile X Syndrome Overview

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hyper methylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.

 

Recent Developmental Activities in the Fragile X Syndrome Market

  • Tetra’s investigational new drug, named BPN14770, can selectively target and inhibit, or suppress, only the PDE4D enzyme. PDE4D plays an important role in cognition. A recent study of over a million healthy human subjects showed connections between genetic variants in PDE4D and years of educational attainment and performance on cognitive tests. Tetra Therapeutics’s BPN14770 targets only PDE4D, and only at specific times of cellular activity. BPN14770 is designed to modulate, rather than completely inhibit, PDE4D. The desired result from clinical trial testing is two-fold: that Tetra’s BPN14770 will improve cognitive function by prolonging cAMP activity, while safety and tolerability are improved because the enzyme is not completely inhibited. Currently it is being investigated in Phase III stage of development.
  • Zygel is being developed for patients suffering from FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). Zynerba Pharmaceuticals is conducting phase III clinical trials for the treatment of Fragile X Syndrome.

 

Fragile X Syndrome Epidemiology Segmentation in the 7MM

  • Total Fragile X Syndrome Diagnosed Prevalent Cases
  • Fragile X Syndrome Gender-specific Diagnosed Prevalent Cases
  • Fragile X Syndrome Age-specific Diagnosed Prevalent Cases

 

Keen to learn how Fragile X Syndrome Market Trends are going to appear in 2032 for the 7MM, Download @ Fragile X Syndrome Market Outlook

 

Fragile X Syndrome Market Insights

Fragile X Syndrome is the known leading cause of inherited intellectual disability and an autism spectrum disorder. Currently, there is no approved treatment for FXS. The treatment relies on the associated symptoms of the disease which are typically managed using pharmacologic interventions, such as stimulants for attention deficit and hyperactivity, selective serotonin reuptake inhibitors (SSRIs) for anxiety, antipsychotic drugs for aggression and mood instability, and melatonin for sleep. In boys with FXS, the most frequently used medications are stimulants. These medications are targeted toward the symptoms of typeractivity, impulsivity, and distractibility and can be quite helpful in these areas.

 

Fragile X Syndrome Emerging Therapies

  • ZYGEL
  • Trofinetide
  • BPN14770
  • Sulindac and others

The launch of the new therapies is expected in the forecast period (2022–2032). Among those, some are in late clinical stages of development, while others are in mid-stage clinical development, have shown promising results.

 

Know more about the driving forces and restraining factors @ Fragile X Syndrome Companies

 

Scope of the Fragile X Syndrome Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 20222-2032
  • Fragile X SyndromCompanies are working such as Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Ovid Therapeutics, Neuren Pharmaceuticals, and others
  • Fragile X Syndrome Pipeline therapies such as ZYGEL (Cannabidiol/ZYN002), BPN14770, Trofinetide, Sulindac (HLX-0201), and others
  • Fragile X Syndrome Unmet Needs, Access and Reimbursement Overview
  • Fragile X Syndrome Market Drivers and Market Barriers

 

Table of Content

1. Key Insights

2. Executive Summary of Fragile X Syndrome

3. Competitive Intelligence Analysis for Fragile X Syndrome

4. Fragile X Syndrome Market Overview at a Glance

5. Fragile X Syndrome Disease Background and Overview

6. Patient Journey

7. Fragile X Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Fragile X Syndrome Unmet Needs

10. Key Endpoints of Fragile X Syndrome Treatment

11. Fragile X Syndrome Marketed Products

12. Fragile X Syndrome Emerging Therapies

List to be continued in the report

13. Fragile X Syndrome (FXS): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Fragile X Syndrome

17. KOL Views

18. Fragile X Syndrome Market Drivers

19. Fragile X Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

For any query related to the report- Fragile X Syndrome Drug Market Report

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/